Roivant Sciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 68 to 72.
This unique rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matched up against all other stocks.
Decades of market research shows that the market's biggest winners typically have an RS Rating of over 80 in the early stages of their moves. See if Roivant Sciences can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Roivant Sciences is trying to complete a cup without handle with a 13.05 buy point. See if it can break out in heavy volume.
The company posted 0% earnings growth last quarter, while sales growth came in at 23%.
The company holds the No. 141 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
